PT - JOURNAL ARTICLE AU - Ekström, Magnus AU - Li, Pei Zhi AU - Lewthwaite, Hayley AU - Bourbeau, Jean AU - Tan, Wan C. AU - Jensen, Dennis AU - , TI - Abnormal breathlessness during cardiopulmonary exercise testing - validation in people with chronic airflow limitation AID - 10.1101/2023.09.11.23295241 DP - 2023 Jan 01 TA - medRxiv PG - 2023.09.11.23295241 4099 - http://medrxiv.org/content/early/2023/09/12/2023.09.11.23295241.short 4100 - http://medrxiv.org/content/early/2023/09/12/2023.09.11.23295241.full AB - Background Exertional breathlessness is the cardinal symptom in cardiorespiratory disease. We aimed to validate recently developed normative reference equations to evaluate breathlessness abnormality during cardiopulmonary exercise testing (CPET) in people with chronic airflow limitation.Methods Analysis of people aged ≥40 years with chronic airflow limitation undergoing CPET in the Canadian Cohort Obstructive Lung Disease (CanCOLD) study. Breathlessness intensity ratings (Borg 0-10 category ratio scale [CR10]) were evaluated in relation to power output (W), rate of oxygen uptake (V’O2), and minute ventilation (V’E) at peak exercise using normative reference equations as: 1) probability of breathlessness normality, defined as the predicted probability of the Borg CR10 rating among healthy references, with lower probability reflecting more severe breathlessness; and 2) presence of abnormal breathlessness, defined as a Borg CR10 intensity rating above the upper limit of normal (ULN). Validity of breathlessness severity (lower probability of normality) and abnormality (>ULN) was evaluated as correlations with relevant participant-reported and physiologic outcomes.Results We included 330 participants (44% women): mean±SD age 64±10 years (range 40– 89), FEV1/FVC 57.3±8.2%, FEV1 75.6±17.9%predicted. Relative to peak W, V’O2 and V’E, abnormal breathlessness was present in 22.7%, 21.5%, and 15.2% of participants, respectively. For all equations, people with abnormal breathlessness had worse lung function, exercise capacity, self-reported symptom burden, physical activity, health-related quality of life, and physiological abnormalities during CPET.Conclusion Evaluation of breathlessness abnormality using CPET normative reference equations was valid in people with chronic airflow limitation.Competing Interest StatementJB and WT report receiving institutional funding for the CanCOLD study from Astra Zeneca Canada Ltd., Boehringer-Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd, Merck, Novartis Pharma Canada Inc., as well as Nycomed Canada Inc. (WT), Pfizer Canada Ltd. (WT), Trudell (JB), and Grifolds (JB). No conflicts of interest exist for any of the other authors.Funding StatementThe CanCOLD study (ClinicalTrials.gov Identifier: NCT00920348) has received support from the Canadian Respiratory Research Network, the Canadian Institutes of Health Research [CIHR/Rx&D Collaborative Research Program Operating Grant 93326], the Respiratory Health Research Network of the Fonds de la Recherche en Sante du Quebec, the Foundation of the McGill University Health Centre and industry partners, including: AstraZeneca Canada Ltd., Boehringer Ingelheim Canada Ltd., GlaxoSmithKline (GSK) Canada Ltd., Novartis, Almirall, Merck, Nycomed, Pfizer Canada Ltd., and Theratechnologies. ME is supported by unrestricted grants from the Swedish Society for Medical Research and the Swedish Research Council (Dnr 2019-02081). HL is supported by a postdoctoral research fellowship from the National Health and Medical Research Council Centre of Research Excellence in Treatable Traits. DJ holds a Canada Research Chair, Tier II, in Clinical Exercise & Respiratory Physiology from the Canadian Institutes of Health Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research ethics board for each participating institution approved the study protocol: UBC/ PHC Research Ethics Board, P05-006 (Vancouver); Biomedical-C Research Ethics Board, BMC-06-002 (Montreal); UHN REB, 06-0421-B (Toronto); Capital Health Research Ethics Board, CDHA-RS/2007-255 (Halifax); Conjoint Health Research Ethics Board, ID21258 (Calgary); DMED-1240-09 (Kingston); 2009519-01H (Ottawa); Bio-REB09-162 (Saskatoon); CER20459 (Quebec City).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data used in the present study cannot be freely shared due to Canadian legal and ethical restrictions, but data may be shared upon reasonable request to the authors and after separate ethical approval.